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conservation of gp41MPER epitopes on ﬁve different clades of HIV-1 in the absence and presence of sCD4. The
binding of human monoclonal antibodies (mAbs) to HIV-1 was dependent upon the virus clade. Soluble CD4
signiﬁcantly increased the accessibility of gp41 MPER-binding epitopes on several isolates that previously
showed little or no binding with 2F5 and 4E10 mAbs as determined by a modiﬁed ELISA-based virus capture
assay and surface plasmon resonance. Studies on the relationship between virus binding and neutralization in
a TZM-bl pseudovirus assay indicated that in most cases, mAbs that exhibited neutralization also bound the
virus. However, neither binding per se nor the total envelope content per virion was a predictor of
neutralization. The hidden or conformational gp41MPER epitopes unmasked by sCD4may provide additional
targets for vaccine design.Antigen Research, Division of
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Understanding the generation of immune responses against HIV-1 is
critical for the further pursuit of developing an effective HIV-1 vaccine,
particularly as they relate to the induction and characterization of virus
neutralizing and binding antibodies as well as antibodies that induce
cellular cytotoxicity. Even though a strong HIV-1 envelope antibody
binding response is induced during the natural course of an infection,
these antibodies usually neutralize heterologous HIV-1 isolates only
weakly. Despite this, a small number of human monoclonal antibodies
(mAbs) that exhibit breadth and potency in terms of neutralization of
primary isolates of HIV-1 from several different clades have been
identiﬁed (Binley et al., 2004; Burton et al., 2005; Zolla-Pazner, 2004).
These mAbs bind to conserved regions of the envelope. 2G12 binds to
speciﬁc oligomannose sequences on gp120, while immunoglobulin
G1b12 (b12) binds to the CD4 binding site (Zhou et al., 2007). Three
other broadly neutralizing mAbs, 2F5, 4E10, and Z13, all target the
membrane proximal external region (MPER) of gp41 (Muster et al.,
1993; Zwick et al., 2001).
The use of a high-throughput neutralization screen of antibody-
containing culture supernatants from activated memory B cells led
to the identiﬁcation of two human mAbs that exhibit HIV-1neutralization breadth and potency with speciﬁcity to the con-
served regions of the V2/V3 loop (Walker et al., 2009). In addition,
several human mAbs that recognize V2 and V3 regions of gp120
have been generated and extensively characterized (Cardozo et al.,
2007; Gorny et al., 1989; Huang et al., 2005; Nyambi et al., 1998,
Pinter et al., 2004; Stanﬁeld et al., 2006). Since the V3 loop is not
exposed on envelope trimers, its importance as a strong vaccine
target is unclear at the present time (Binley et al., 2004; Burton et
al., 2004; Lusso et al., 2005).
HIV-1 entry into a target cell is a well-orchestrated multistep
process, initially involving the viral envelope proteins gp120 and gp41.
After the initial step of gp120 binding to the CD4 receptor, a
conformational change occurs in the gp120 molecule, which exposes
the binding sites for the chemokine receptors CXCR4 or CCR5 that
serve as the coreceptors (Berger et al., 1999; Doms, 2000). This
interaction in turn induces another conformational change that allows
the binding of gp41 molecule followed by the fusion of the viral lipid
bilayerwith the plasmamembrane bilayer of the target cell. This fusion
results in the entry of the viral RNA into the target cell (Colman and
Lawrence, 2003). During the course of these interactions as well as
during the budding of the virus, lipid-associated proteins (Wyatt and
Sodroski, 1998) and even lipids themselves (Haynes et al., 2005;
Sánchez-Martínez et al., 2006) are exposed. Thus, these regions could
serve as potential antigenic targets for virus neutralization (Alving et
al., 2006) as demonstrated by the production of multispeciﬁc murine
IgM mAbs that simultaneously bind to lipids and also to gp41 MPER
regions and neutralize HIV-1 infection in a PBMC neutralization assay
(Matyas et al., 2009b).
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entry and various models have been proposed to explain the different
conformational states. At least three distinct conformational states, a
pre-fusion conformation, a gp41-pre-hairpin intermediate, and a post-
fusion trimer of hairpin have been reported (Chan and Kim, 1998;
Harrison 2008). There are several studies examining the role of mAbs
2F5 and 4E10 during these conformational states. Using 293T cells
transiently expressingHXB2 envelope or HXB2 pseudovirions, de Rosny
et al. (2004) demonstrated that mAb 2F5 bound to both native and
fusion intermediate forms of gp41 and neutralized virus at a late step in
virus entry. In another study using a pseudovirus envelope mutant that
consisted of gp120 covalently attached to gp41, Binley et al. (2003)
showed that 2F5 and4E10neutralized effectively in thepost attachment
conformation. In contrast, two other studies (Frey et al., 2008; Alam
et al., 2009) have proposed a two-stepmechanism for the neutralization
of HIV-1 by MPER-speciﬁc antibodies. In the ﬁrst step, mAbs 2F5 and
4E10 bind to the lipids on the viralmembrane. The second step involves
the binding of the mAbs to the receptor-triggered pre-hairpin
intermediate conformation. Speciﬁc interactions between 4E10 and
membrane lipid components and their role in neutralization have also
been reported by Xu et al. (2010).
Virus capture assays can be utilized to address the issue of mAbs
binding to the native virion surface. The virus capture assay initially
developed by Nyambi et al. (2001) primarily concentrated on antigenic
epitopes in the gp120 region of the intact virus of different clades and
utilized a panel of human monoclonal antibodies directed mainly
against this region (Nyambi et al., 2000). The assaywas used tomap the
epitopes exposed on intact native primary HIV-1 and also to study the
conformational changes that occurred in the presence of sCD4 (Mbah
et al., 2001). Many V3 reactive mAbs do show breadth and potency of
neutralization once the site is exposed after binding to sCD4 (Wu et al.,
2008). Studies on the exposure of gp41 epitopes on virions in the
presence of soluble CD4 are however limited (Crooks et al., 2005;Moore
et al., 2006; Nyambi et al., 2000).
An in-solution virus capture assay was recently developed to
examine the accessibility of MPER epitopes on clade B pseudoviruses
(Leaman et al., 2010). This assay reduces envelope independent
capture of virions. Env-speciﬁc antibodies can bind to non-functional
gp120 molecules in a virus capture assay and therefore do not
necessarily correlate with virus neutralization (Poignard et al., 2003;
Moore et al., 2006). Given that p24 is an indirect marker of virus, the
use of an infection-based readout would be more desirable (Poignard
et al., 2003). However, replication competent luciferase reporter HIV-
1 are not readily available for all clades. In view of this, p24 is used as a
measure of virus binding in virus capture assays (Moody et al., 2010).
In the current study, we utilized human monoclonal antibodies to
investigate the accessibility and conservation of gp41MPER epitopes on
twopseudoviruses each fromcladesA, B, C, D, andCRF01_AE. The results
demonstrate that sCD4 increased the accessibility of the gp41 binding
epitopes on some of the pseudoviruses as determined by the virusTable 1
HIV-1 clades, abbreviation, and epitopes for 2F5, 4E10 with glycosylation sites for 2G12.
Clade Virus name Abbreviation 4E10 sequenc
A 93RW_024 93RW TWFDIS
00KE_KNH1144 KHN NWFDIS
B BAL BAL-PV NWFDIT
US-1 PV US-1 PV SWFSIT
C PBL 286(696) PBL 286 SWFSIT
PBL 288(411) PBL 288 SWFSIT
D 98UG_57128 57128 NWFSIT
99UG_A07412M1 A07412 NWFSIT
CRF01_AE CM 235 CM 235 NWFDIT
NI1149 NI NWFDIS
aN-sites examined 295, 332, 339, 386 and 392. Mutations in amino acids in the 4E10 andcapture assay and surface plasmon resonance. The relationship between
virus binding and neutralization in a TZM-bl pseudovirus assaywas also
examined.
Results
Binding of human mAbs 4E10, 2F5, and 2G12 to pseudovirus isolates
from different HIV-1 clades
The HIV-1 isolates used in the present study were CCR5-tropic
pseudoviruses belonging to ﬁve different clades. 93RW is a dual tropic
virus. The virus clade, name, abbreviation, their 2F5 and 4E10 epitope
binding sequences, and the glycosylation sites for 2G12 are presented in
Table 1. In the virus capture assay used by Poignard et al. (2003), IgG
anti-Fc-speciﬁc antibodywas used to coat thewells prior to the addition
of the capture antibodies. In our assay, proteinGcoatedplateswereused
to bind the antibodies through their Fc regions thus allowing the
antibody combining sites to be available for virus binding (Bjorck and
Kronvall, 1984). As shown inFig. 1A andB,mAbs4E10and2F5exhibited
moderate to high binding to clades A (82–231 pg/ml), B (BAL-PV; 120–
340 pg/ml), and D (60–250 pg/ml) pseudoviruses. Clade CRF01_AE
psuedoviruses, CM235andNIboundmoderately to4E10(55–60 pg/ml)
but poorly to 2F5 (0–22 pg/ml). Clades B (US-1 PV) and C (PBL 288)
pseudoviruses exhibited extremely low binding to 4E10 (22 pg/ml and
49 pg/ml, respectively) and no binding to 2F5 mAbs (0 pg/ml; Fig. 1B).
Another clade C pseudovirus, PBL 286 did not bind 4E10 or 2F5 mAbs.
The 4E10 and 2F5 binding epitopes for all the viral isolates tested are
shown in Table 1. Although the 4E10 epitope [NWF(D/N)IT] was intact
in both BAL-PV and CM235, BAL-PV bound 4E10 at a higher level
compared to CM235. Both the clade C viruses as well as US-1 PV have
mutations in positions 1 (asparagine to serine) and 4 (aspartic acid or
asparagine to serine) of the 4E10 binding site and exhibited low to no
binding to the virus. It appears that the ﬁrst amino acid in the epitope
(asparagine) may be critical for determining the strength of binding to
the virus, since both cladeD viruses bound4E10at high levels, in spite of
having serine in position 4 of the epitope.
There was no mutation in the 2F5 binding epitope (ELDKWA) for
BAL-PV, US-1PV, and CM235; yet the 2F5 binding proﬁles varied greatly.
BAL-PV bound 2F5 at high levels while the other two viruses exhibited
no binding. Clade C viruses usually do not exhibit 2F5 binding since the
2F5 binding epitope is mutated. The two clade C viruses used in the
present study, PBL 286 and PBL 288, are mutated at the ﬁrst and last
amino acid of the 2F5 binding epitope and as predicted did not bind to
2F5. Thesedata indicate thatmAbs4E10and2F5exhibit varyingdegrees
of binding to the viruses even though the 4E10 and 2F5-binding
epitopes may be conserved within or between clades.
Variable cross-clade binding (clades A through D; 0–257 pg/ml)was
observed with mAb 2G12 (Fig. 1C). Mutations at any of the 5
glycosylation sites on gp120 at positions 295, 332, 339, 386, and 392
that are important for the binding of mAb 2G12 are shown in Table 1.e NWF(D/N)IT 2F5 sequence ELDKWA 2G12 Nsite mutationsa
ALDKWA S339
ALDKWA None
ELDKWA None
ELDKWA None
ALDKWQ None
ALDKWK None
KLDSWA None
QLDKWA D295 and G 339
ELDKWA E332
ELNKWA E332
2F5 epitope are underlined.
Table 2
Comparison of 2F5 and 4E10 binding to HIV-1 and TZM-bl pseudovirus neutralization
assay.a
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C pseudoviruses (Fig. 1C) even though the 5 glycosylation sites were
intact in both cases. A reduction in the binding of the antibody to the4E10
2F5
Tetanus
Toxoid
2G12
USHIV+
A
C
B
D
E
400
300
200
0
100
400
300
200
0
100
400
300
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0
100
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300
200
0
100
30
20
10
0
600
p2
4 
(p
g/m
l)
Clade Virus Virus capture TZM-bl Neut IC50 μg/ml
4E10 2F5 4E10 2F5
A 93RW +++ ++ N25 6.07
KNH ++ ++ 16.2 0.06
B BAL-PV +++ ++ 5.65 1.64
US-1 PV + − N25 1.8
C PBL 286 − − 8.08 N25
PBL 288 + − 4.46 N25
D 57128 +++ + 11.65 N25
A07412 +++ ++ 2.18 5.48
CRF01_AE CM 235 + + 0.35 0.08
NI + − 1.35 N25
a p24 concentrations: −, no binding (b 15.4 pg/ml); +, weak binding (16–75 pg/
ml); ++, moderate binding (76–150 pg/ml); +++, strong binding (N221 pg/ml). See
Material and Methods for more details.virus (with the exception of 93RW)was observedwhen amutationwas
present at any of the glycosylation sites.
Although, USHIV+ plasma pool (Fig. 1D) was derived from clade B
infected individuals, it exhibited variable cross-clade binding to clades A
through AE viruses (21 pg/ml–476 pg/ml). MAb (Hyb 278-01) speciﬁc
to tetanus toxoid (negative control) was examined for binding to all 10
of thepseudoviruses used in the study (Fig. 1E). The p24valuesobtained
with anti-tetanus toxoid for all of the viral isolates tested ranged from 0
to 7.7 pg/ml. Therefore, a p24 value greater than or equal to twice the
negative control (15.4 pg/ml) for the test samples was considered
positive. The datawere analyzed after the p24 value obtainedwith virus
alone (in the absence of antibody) was subtracted from all the test
samples.Comparison of virus binding and neutralization
The relationship between the binding of the mAbs 4E10 and 2F5 to
the virus, and their ability to neutralize the virus in a TZM-bl
pseudovirus assay is shown in Table 2. The data for the virus binding
are derived from Fig. 1. The binding and the neutralization experiments
were conducted independently. The TZM-bl pseudovirus assay neutral-
ization data is presented as IC50 (μg/ml). The highest concentration of
mAbs tested for neutralization was 25 μg/ml. As shown in Table 2, the
different clades of HIV-1 tested, showed varying degrees of binding and
neutralization to 2F5 and 4E10. Based on the binding and neutralization
by4E10or 2F5mAbs (Table 2), viruses can be grouped into three or four
categories. (i) viruses (KNH, BAL-PV, PBL 288, 57128, A07412, CM235,
andNI) that bind to and are neutralized by4E10; (ii) viruses (93RW,US-
1 PV) that bind but are not neutralized by4E10; (iii) virus (PBL286) that
does not bind but is neutralized by 4E10. Based on the binding and
neutralization by 2F5mAb, the different clades of HIV-1 tested could be
grouped into four categories. (i) viruses (93RW, KNH, BAL-PV, A07412,
and CM235) that bind to and are neutralized by 2F5; (ii) virus (57128)
that binds to but is not neutralized by 2F5 mAb; (iii) viruses (PBL 286,Fig. 1. Binding patterns of various human monoclonal antibodies to different HIV-1
clades. The binding of HIV-1 pseudoviruses (100 ng/ml) to 4E10 (panel A), 2F5 (panel
B), 2G12 (panel C), USHIV+ plasma pool (panel D) and control antibody Hyb 278-01
against tetanus toxoid (panel E) were examined. The amount of virus bound to each of
the mAbs was determined by measuring the amount of viral p24 bound (pg/ml) as
described in the Materials and Methods. The p24 value obtained with virus alone (in
the absence of antibody) was subtracted from all the test samples. The p24 values for
the negative control Hyb278-01 (anti-tetanus toxoid antibody) for all viral isolates
tested ranged from 0 to 7.7 pg/ml (background value). Therefore a p24 value≥15.4 pg/
ml, which was twice the background value was considered positive. The average of
duplicate wells of 3–5 experiments±S.D. is shown.
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Fig. 2. SDS-PAGE analysis of viral proteins stained with ﬂuorescent dyes. Concentrated virus preparations were lysed and the viral proteins were analyzed on a gradient gel under
reducing conditions. The ﬁgure shows images for Pro-Q® Emerald 300 (panels A and B) and SYPRO® Ruby (panels C and D) staining for quantiﬁcation of glycoprotein and total
protein, respectively. Panels A (gel stained with Pro-Q® Emerald 300) and C (gel stained with SYPRO® Ruby) contain the following: Molecular weight markers (MW range from180
kDa to 14 kDa); lane 1: 93RW (clade A); lane 2: KNH (clade A); lane 3: BAL-PV (clade B); lane 4: PBL 288 (clade C); lane 5: US-1 PV (clade B). Panels B (gel stained with Pro-Q®
Emerald 300) and D (gel stained with SYPRO® Ruby) contain the following: Molecular weight markers (MW); lane 1: PBL 286 (clade C); lane 2: 57128 (clade D); lane 3: A07142
(clade D); lane 4: CM235 (clade CRF01_AE); lane 5: NI (clade CRF01_AE). Lanes 6 through 10 in panels A, B, C, and D contain the standards, gp140 and p24. Lane 6: (90 ng gp140;
1200 ng p24); lane 7: (45 ng gp140; 600 ng p24); lane 8: (22.5 ng gp140; 300 ng p24); lane 9: (11.25 ng gp140; 150 ng p24); lane 10: (5.6 ng gp140; 75 ng p24). Arrows denote the
position of gp140 and p24 on the gel. The position of gp120 and gp160 are depicted by (*) and (**), respectively.
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(iv) virus (US-1 PV)which does not bind but is neutralized by 2F5mAb.
Quantitative measurements of envelope and p24 from pseudoviruses
Fig. 2A, B, C, and D shows the results from SDS-PAGE analysis of viral
proteins from the pseudoviruses examined in Fig. 1 after staining with
PRO-Q® Emerald 300 (panels A and B) and SYPRO Ruby (panels C and
D). Analysis of theﬂuorescent dye-stained gels by ImageJ corresponding
to gp160, gp120, and p24 for a given sample allows semiquantitative
estimation of p24 and gp120 present in the virions. This is achieved by
running known amounts of gp140 and p24 on each gel and generating a
standard curve. Table 3 shows the calculated ng for gp160, gp120, and
p24. The ratio of p24:gp120(fmol/fmol) ranged from4.5 to19.3 for all ofTable 3
Semi-quantitative envelope/p24 analysis.
Virus gp 160 (ng) gp 120 (ng) gp 120 (fmol) p24 (ng)
93RW 173 139 1.16 536
KNH 126 77 0.64 216
US-1 PV 33 42 0.35 –
BAL-PV 31 14 0.12 12.9
PBL 288 105 60 0.50 221
PBL 286 1593 306 2.55 684
57128 943 146 1.22 349
A07412 996 149 1.24 318
CM235 1388 196 1.63 441
NI 608 88 0.73 247theviral isolates tested. Althoughwe coulddetect thep24band forUS-1,
it was not in the linear portion of the standard curve and was therefore
omitted from the calculation. The number of trimers per virion (Table 3)
were calculated based on an estimate of approximately 1400 gag
molecules per virion and an average Gag:Env ratio of approximately
60:1 (mol/mol), corresponding to about 8 envelope trimers per virus
particle (Louder et al., 2005). The number of trimers/virion were fairly
consistent among all the pseudoviruses tested with the exception of
BAL-PV which had approximately 107 trimers/virion compared to an
average of 36 trimers/virion. Western blotting (Fig. 3) conﬁrmed the
results of the ﬂuorescent SDS-PAGE analysis (Fig. 2). The gels were
probed with USHIV+ sera (Fig. 3A and B). The HIV protein speciﬁcity of
the bandswas conﬁrmed byprobing a separate blotwith normal human
sera (Fig. 3C). A major band observed at approximately 65 kDa in thep24 (fmol) p24 /gp120 fmol/fmol Trimers per virion (1400 Gag/viron)
22.33 19.3 24.9
9.0 14.1 34
– – –
0.54 4.5 106.7
9.21 18.4 26.1
28.5 11.2 42.9
14.54 11.9 40.3
13.25 10.7 44.9
18.4 11.3 42.5
10.29 14.1 34.0
AB
C
Fig. 3. Western blot analysis of viral proteins. Proteins from the pseudoviruses separated
bySDS-PAGEwereblottedontoPVDFmembranes andprobedwithUSHIV+sera (panelsA
and B) or with normal human sera (panel C). The molecular weight markers (MW range
from 180 kDa to 6 kDa) are shown to the left of each of the panels. Panel A contains the
viral proteins from the following pseudoviruses: 93RW, KNH (clades A); US-1 PV, BAL-PV
(clade B); PBL 288 (clade C). Panels B and C contains the viral proteins from the following
pseudoviruses: PBL 286 (clade C); 57128, A07412 (clade D); CM235, NI (clade CRF01_AE).
The standards (S1-S5) are depicted in each of the panels. S1: 400 ng gp140 and 1200 ng
p24; S2: 200 ng gp140 and 600 ng p24; S3 100 ng gp140 and 300 ng p24; S4: 50 ng gp140
and 150 ng p24; S5: 25 ng gp140 and 75 ng p24.
A B
Fig. 4. BN-PAGEWestern blots of pseudovirus envelope species. Proteins from the pseudoviruse
cocktail (panelA)orwith anti-gp41 cocktail (panelB). Themolecularweightmarkers (MWrang
the viral proteins from the following pseudoviruses: 93RW, KNH (clades A); US-1 PV, BAL-PV (
40 ng gp140; S2: 20 ng gp140; S3: 10 ng gp140; and S4: 5 ng gp140. Monomers and trimers a
217K.K. Peachman et al. / Virology 408 (2010) 213–223ﬂuorescent gels (Fig. 2) was not an HIV protein as it was not detected in
the Western blot and might represent serum albumin from the cell
culture supernatants.
Identiﬁcation of different forms of envelope on pseudoviruses by Native
Blue-PAGE gels
The presence of envelope monomers and trimers on all the
pseudoviruses used in this study were examined on a 4–16% Bis-Tris
NuPAGE gel followed by Western blotting (Fig. 4). To extract envelope
proteins from the pseudoviruses, 1% digitoninwas used. The data from5
of the 10 pseudoviruses examined (93RW, KNH, US-1 PV, BAL-PV, and
PBL 288) are shown in Fig. 4. BN-PAGE blots gave weaker bands than
those observedwith SDS-PAGEWestern blots (Fig. 3). The blots in Fig. 4
were probedwith either anti-gp120mAb cocktail (Fig. 4A) orwith anti-
gp41 cocktail (Fig. 4B). The blots also contained 5 ng to 40 ng of CHO-
expressed gp140. Two bands were detected with the anti-gp120 mAbs
(Fig. 4A, lanes S1–S4). These corresponded to gp140 trimers and gp140
monomers (indicated by arrows). Two additional bands (indicated by
arrows) corresponding to gp41 trimers and gp41 monomers were
detected with anti-gp41 mAbs (Fig. 4B, lanes S1–S4). All 5 pseudo-
viruses showed a band around 440 kDa, which is likely to be gp120/
gp41 trimers (Figs. 4A and B). The second band around 160 kDa appears
to be gp120/gp41 monomers as it was detected by both mAb cocktails.
In Fig. 4B, two faint bands could be distinguished, which could
correspond to trimeric and monomeric gp41.
Effect of soluble CD4 on the binding of mAb 2F5 and 4E10 to HIV-1
The accessibility of gp41 epitopes on intact virions to 2F5 and 4E10
was examined in the virus capture assay in the absence and presence of
sCD4. As shown in Fig. 5, the binding of 2F5 and 4E10 in the absence
(closed bars) or presence of 15 μg of soluble CD4 (open bars) to clades A,
B, C, D, and CRF01_AE viruses was examined. The presence of sCD4
resulted in a signiﬁcant increase (p≤0.05) in the binding of 2F5 to clade
A (93RWand KNH; panel A) and clade CRF01_AE (CM235 andNI; panel
E) viruses. No signiﬁcant increases were observed in binding to clade B
(US-1 PV and BAL-PV; panel B), clade C (PBL 288, PBL 286; panel C), and
clade D (57128, A07412; panel D) viruses, although there was a trend
towards signiﬁcant binding of 2F5 to PBL 288 in the presence of sCD4.
In the presence of 15 μg of sCD4 (Fig. 5), a signiﬁcant increase
(p≤0.04) in the binding of 4E10 to clade A (93RW; panel F) and clade C
(PBL 286; panel H) viruseswas observed. The binding of another clade A
(KNH; panel F), clade B (US-1 PV and BAL-PV; panel G), clade C (PBL
288; panel H), clade D (57128 and A07412; panel I), and clade AE
(CM235andNI; panel J) viruses to4E10wasnot signiﬁcantly affectedby
the addition of sCD4. The above results indicate that binding of sCD4s separated by BN-PAGEwere blotted onto PVDFmembranes and probedwith anti-gp120
e from669 kDa to66 kDa) are shown to the left of eachof thepanels. PanelsA andB contain
clade B); PBL 288 (clade C). The standards (S1-S4) are depicted in each of the panels. S1:
re indicated by arrows.
DCA B
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Fig. 5. Effect of soluble CD4 on the binding of mAbs 2F5 and 4E10 to intact HIV-1. The binding of 2F5 and 4E10 in the absence (closed bars) or presence of 15 μg (open bars) of soluble
CD4 to clades A (panels A, F), B (panels B, G), C (panels C, H), D (panels D, I), and AE (panels E, J) viruses was determined by the virus capture assay. HIV-1 and sCD4were added at the
same time to the virus capture plates. The amount of virus captured by 2F5 and 4E10mAbs was determined based on the p24 value. The data represent the average of duplicate wells
of 3–4 experiments±S.D. A signiﬁcant increase in binding is denoted by (*).
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isolates.
Binding of 2F5 and 4E10 to AT-2 inactivated virus as determined by
surface plasmon resonance
We further veriﬁed the effect of sCD4on the binding of 2F5 and 4E10
to HIV-1 by surface plasmon resonance using AT-2 inactivated virus. In
order to establish that AT-2 inactivation of the virus did not impact the
bindingofmAb2F5, AT-2 cladeDvirusA07412was immobilized onaC1
Biacore chip (2800 RU). The binding of different concentrations of 2F5
(0–1000 nM) to the virions was analyzed and is represented as a
sensogram (Fig. 6A). There was a dose-dependent increase in the
binding of 2F5. Alternatively, 2F5 and 4E10 or USHIV+ sera or normal
human sera were immobilized on a CM5 Biacore chip and the binding
(RU) to AT-2 clade D virus A07412 was analyzed. A representative of
two separate experiments is shown in Fig. 6B. A 5- to 6-fold higher
bindingofmAbs2F5 and4E10aswell USHIV+sera toAT-2 cladeDvirus
A07412 was obtained compared to pooled normal human sera. Fig. 6A
andBdemonstrates that AT-2 inactivation did not destroy the 2F5 or the
4E10 binding epitopes on the virions.
Effect of soluble CD4 on the binding of mAbs 2F5 and 4E10 to HIV-1 as
determined by surface plasmon resonance
Only two of the pseudoviruses (clade A KNH; clade D A07412) used
in Fig. 5 were available as AT-2 inactivated viruses and were utilized in
the Biacore studies. Protein G was immobilized on a CM5 chip followedby the addition of 25 μg/ml of 2F5, 4E10, or control antibody Hyb 278-
01. AT-2 clade A (KNH) and clade D (A07412) viruses were incubated
with sCD4 (0, 1, 5, and 10 μg/ml) before addition to the CM5 chip
containing the boundmAbs. As shown in Fig. 7, the addition of 10 μg/ml
of sCD4 signiﬁcantly increased (p=0.04) the binding of 2F5 to KNH
virions. Clade D A07412 virus did not show a similar signiﬁcant increase
in binding to 2F5 or 4E10mAbs in the presence of sCD4. The resultswith
clades A and D viruses were similar to those obtained with sCD4 in the
virus capture assay (Fig. 5). These data indicate that accessibility of 2F5
and 4E10 epitopes depends upon the virus clade.
Discussion
The envelope protein of HIV-1 has always been considered as a
potential vaccine target for the generation of neutralizing antibodies. In
particular, the envelope protein gp41 has been the focus of attention as
three broadly neutralizing mAbs that bind to the MPER region of gp41
have been described. MAbs 2F5 and 4E10 not only demonstrate
speciﬁcity to the MPER region of gp41 but also speciﬁcally bind to
various lipids (Haynes et al., 2005; Matyas et al., 2009a; Sánchez-
Martínez et al., 2006). Binding of the antibodies to lipids could be part of
the neutralizing mechanism (Sánchez-Martínez et al., 2006; Alving
et al., 2006). It has been demonstrated thatmurine IgMmAbs aswell as
several human IgG mAbs that exhibited binding to pure phospholipids
neutralized HIV-1 infection in a PBMC assay (Brown et al., 2007; Moody
et al., 2010). Similarly, murine multispeciﬁc IgM mAbs that simulta-
neously bind to lipids and gp41 MPER regions also neutralized HIV-1
infection in a PBMC assay (Matyas et al., 2009a,b).
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Fig. 6. Determination of the binding of mAbs 2F5 and 4E10 to AT-2 inactivated virus by
surface plasmon resonance. Panel A: AT-2 clade D virus A07412 was immobilized on a
C1 Biacore chip (2800 RU) and the binding of different concentrations of 2F5 (0–
1000 nM) to the virions is represented as a sensogram. Panel B: MAbs 2F5 and 4E10 and
USHIV+ sera and normal human sera (NHS) were immobilized on a CM5 Biacore chip
and the binding of AT-2 clade D virus A07412 was analyzed. The binding (response
units, RU) is depicted as a bar graph. A representative experiment is shown.
219K.K. Peachman et al. / Virology 408 (2010) 213–223Although, the exactmechanism(s) of neutralization by 2F5 and4E10
are not fully understood, they appear to interfere with the fusion of the
virus with the target cell and not with the initial binding step. Since the
binding, fusion, and entry of HIV-1 is a highly complex and intricate
process involving protein–lipid interactions, there are several studies
that have reported that the mAbs 2F5 and 4E10 bind to both the native
and fusion intermediates of gp41 (Chan and Kim, 1998; Harrison 2008;
de Rosny et al., 2004; Binley et al., 2003) and thus are available for
binding throughout the viral entry process, while other studies have
reported that the neutralization epitopes on the virus may be visible
only for very short periods of time(Frey et al., 2008;Alamet al., 2009). In0 1 5 10
Clade A (KNH)
sCD4 (µ
C
Fig. 7. Effect of sCD4 on the binding of mAbs 2F5 and 4E10 to HIV-1 virions by surface plas
25 μg/ml of 2F5, 4E10, or control antibody Hyb 278-01. AT-2 clades D (A07412) and A (KNH)
the CM5 chip containing the boundmAbs. The response units are depicted as a bar graph. The
denoted by (*).order to design better immunogens as potential vaccine candidates, it is
important to map the epitopes visible on intact virions and also to
examine if epitopes that are critical for virus binding or fusion can be
made accessible.
Previously, a virus capture assay developed by Nyambi et al. (2000)
was utilized tomap the epitopes exposed on intact virions using human
anti-gp41 cluster I and II antibodies in addition to antibodies directed
against the V2, V3 loop, and CD4 binding domain. In their study, the six
mAbs tested to the cluster II region did not bind or bound poorly to the
isolates examined. In the present study, the virus-binding assay was
modiﬁed to determine the binding of humanmAbs that recognizeHIV-1
gp41 epitopes. Protein G coated ELISA plates were used to bind the
antibody before capture of the virus. Using this assay, we analyzed the
binding of three human anti-envelope mAbs to pseudoviruses from
clades A, B, C, D, and CRF01_AE (2 pseudoviruses from each of the
clades). We chose to concentrate only on pseudoviruses as this
eliminates the potential complexities, which could be introduced by
primary and T cell adapted viruses.
In our studies, mAb 2G12 bound to at least one of the viral isolates
from each of the 5 clades tested. The binding of mAb 2G12 is dependent
upon 5 glycosylation sites on gp120 at positions 295, 332, 339, 386, and
392.Mutations at any of the glycosylation sites resulted in a reduction in
binding of the antibody to the virus with the exception of 93RW. Our
data suggest that the glycosylation sites aswell as the accessibility of the
mannose residues on the virion inﬂuence the binding characteristics.
Similarly, HIV-1 clade B positive plasma pool USHIV+ bound all of the
10 isolates tested. Although the plasma pool was from persons infected
with clade B virus, it also recognized clades A, B, C, D, and CRF01_AE
viruses. The plasma pool therefore contained polyclonal antibodies that
cross-reacted with envelope proteins from other clades.
93RW and BAL-PV were captured at a higher level by all Abs tested,
whereas US-1 PV and PBL 288 were captured at signiﬁcantly lower
levels. In order to determine if these differences in virus capture were
related to the envelope concentrations, the amount of envelope on the
pseudoviruses were quantiﬁed. 93RW and BAL-PV had 139 ng and
14 ng of gp120, while US-1 PV and PBL 288 had 42 ng and 60 ng of
gp120, respectively. These data demonstrated that there was no
correlation between the envelope content and virus binding. In the
pseudovirus preparations tested, the number of envelope spikes per
virus ranged from 25 to 107. The trimers per virion also were not
predictive of high or low binders in the virus capture assay.
To account for alternative forms of the envelope to explain the
different amounts of virus captured, we examined the pseudovirus
envelope proteins on native blue gels followed by Western blotting.
Probing with an anti-gp120 mAb cocktail revealed the presence of two
bands in the lanes loaded with commercially obtained gp140. These
bands are likely to be trimers of gp140 and gp140monomers.When theg/ml)
1 5 10
2F5
4E10lade D (A07412)
0
mon resonance. Protein G was immobilized on a CM5 chip followed by the addition of
viruses were incubated with sCD4 (0, 1, 5, or 10 μg/ml) for 1 h at 37 °C before addition to
data represent the average of 3–4 experiments±S.D. A signiﬁcant increase in binding is
220 K.K. Peachman et al. / Virology 408 (2010) 213–223gels were probed with anti-gp41 mAb cocktail, two additional bands
corresponding to gp41 trimers and gp41monomerswere also observed.
PBL 288 and US-1 PV had very low trimers. 93RW, KNH, and BAL-PV all
had gp160 trimers and very low levels of gp160 monomers and gp41
trimers. With the other ﬁve viruses, it was difﬁcult to come to a
conclusive decision about the various species of trimers and monomers
(data not shown). 93RW, KNH, and BAL-PV all bound viruses at
moderate to high levels and this binding is probably reﬂective of binding
to the envelope trimers. However, these envelope trimers could consist
of both functional and nonfunctional species.
It is interesting to note that although 4E10 bound very strongly and
2F5 exhibited moderate binding to 93RW in the virus capture assay,
4E10 did not neutralize the virus in a TZM-bl pseudovirus assay when
tested at 25 μg/ml, however, 2F5 did neutralize the virus. The lack of
correlation between binding of the different mAbs and neutralization
may be the due to several reasons. If binding to non-functional trimers
(Crooks et al., 2005; Poignard et al., 2003) was the sole reason for this
discrepancy, then both 4E10 and 2F5 should have exhibited similar
neutralization characteristics, which was clearly not the case. It is well
established that the lipid binding proﬁles for 2F5 and 4E10 are different
(Haynes et al., 2005; Matyas et al., 2009a). Therefore, the binding of the
mAbs and the neutralization proﬁles could be inﬂuenced by the lipids
that are incorporated into the viral envelope. Another possibility for the
strong binding and a lack of neutralization could be due to themutation
of the 4E10 binding epitope. The amino acid sequence could contribute
tovariationsobservedbetweenbinding andneutralization. Even though
the antibodies bind the virus they may not be able to inhibit viral entry
and/or viral assembly.
There was an association between binding and neutralization by
4E10 in 7 out of the 10 viral isolates tested. Two of the isolates were
bound butwere not neutralized by 4E10. Another isolate (PBL 286)was
neutralized by 4E10 but was bound by 4E10 only in the presence of
sCD4. Therefore, 4E10 bound and neutralized 8 out of the 10 viral
isolates tested. Five of the 6 viral isolates that 2F5 bound were also
neutralized by 2F5, while 4E10 bound and neutralized 4 of these same
viral isolates. The above results indicate that binding per se does not
determine the neutralization ability of the mAb.
Mbah et al. (2001) have demonstrated that sCD4 binding causes
conformational changes leading to the exposure of epitopes in the V2
and V3 regions of gp120 resulting in a 2- to 22-fold increase in antibody
binding in 7 out of the 8 intact virions tested. Their study also reported
that therewerenochanges in the cluster I and II regionsof gp41after the
addition of sCD4 thereby suggesting that there was no further increase
in the exposure of gp41 epitopes. We found similar results (data not
shown) as Mbah et al. (2001), in terms of a lack of increase in 2F5
binding to 92UG in the presence of sCD4. However, our study showed a
signiﬁcant increase in both 2F5 and 4E10 binding in the presence of
sCD4 with 93RW, a different clade A isolate. In addition, a signiﬁcant
increase in 2F5 binding in the presence of sCD4was observedwith clade
A (KNH) and clade AE (CM 235 and NI) viruses.
Addition of sCD4 to clade C PBL286 virus resulted in binding to 4E10,
whichwas previously absent suggesting that although the 4E10 epitope
was present, it was inaccessible and not exposed on the surface of the
virion. Thismaybedue to the fact that the4E10antibody-binding site on
gp41 is close to the viral lipid bilayer and is normally not easily
accessible. In clade C viruses, since the 2F5-binding site is mutated, the
mAbdidnot bind to the virus and thebinding characteristics also did not
signiﬁcantly change with the addition of sCD4. Similarly sCD4 did not
signiﬁcantly enhance the binding of clades B and D viruses to either 2F5
or 4E10. It is possible that sCD4 not only induces conformational
changes in the gp120 region of the envelope but also in the gp41 region.
There might be subtle differences in the conformational changes
between the different HIV-1 clades that could not only provide greater
accessibility of the gp41 epitopes for antibody binding in some clades
and not in others but also inﬂuence the neutralization proﬁles. It has
been reported that pre-incubation of the virus with sCD4 substantiallyincreased the sensitivity of subtype B viruses to neutralization by the V3
mAbs (Wu et al., 2008).
Surface plasmon resonance was used to conﬁrm the sCD4 results
obtained with the modiﬁed virus capture assay. Binding of AT-2
inactivated viral isolates to both 2F5 and 4E10 in the presence and
absence of sCD4 was analyzed using the Biacore. Due to the
unavailability of the isolate-speciﬁc AT-2 inactivated virus, all of the
isolates used in the virus capture assay could not be tested using the
Biacore. Chemical inactivation of the virus with AT-2 did not destroy or
alter the 2F5 or 4E10 binding epitopes as demonstrated by Biacore
analysis. A dose-dependent increase in binding of 2F5 to clades D virus,
A07412,wasobserved. Addition of sCD4didnot signiﬁcantly enhance or
decrease the binding of both 2F5 and 4E10 to clade D virus A07412.
These results were similar to the results obtained with the modiﬁed
virus capture assay. A signiﬁcant increase in the binding of 2F5 but not
4E10 to clade A isolate KNH in the presence of sCD4 was observed. Our
studies demonstrate that sCD4 binding causes a signiﬁcant increase in
the accessibility of gp41 epitopes on the intact virus of certain isolates,
leading to an increase in binding of 2F5 and 4E10 to the virus. The virus
capture assay and the Biacore studies demonstrate that sCD4 facilitates
the accessibility of gp41 epitopes on intact virions of certain isolates.
However, it is not clear whether the increase in binding in the presence
of sCD4 is because of binding to functional trimers or to sCD4 induced
non-functional trimers as reported by Haim et al. (2009). It has been
proposed that 2F5 and 4E10 epitopes are only exposed for antibody
binding within the gp41 pre-hairpin intermediate (Frey et al., 2008;
Alam et al., 2009). However, our data demonstrate that CD4 engage-
ment is not required forMPER epitope binding since both 2F5 and 4E10
mAbs recognize viral structures before and after CD4-induced envelope
activation.
It is still not clear what determinants on the envelope should be the
target of neutralizing antibodies. It might be important to target several
regions of the envelope for the induction of neutralizing antibodies in
order to prevent entry, replication, and budding of the virus. Thus it is
important to identify the protein and lipid epitopes on the surface of
intact virions that are cross-clade binding. Some of these epitopes may
be conformational and exposed only after interaction with the CD4
receptor. These are some important aspects to consider while designing
aHIV-1vaccine thatwould generate cross-cladeneutralizingantibodies.
Materials and methods
Pseudoviruses and antibodies
Pseudoviruseswere prepared by transfecting 5×106 293 T cellswith
8 μg of env expression plasmid and 24 μg of an env-deﬁcient HIV-1
backbone vector (pSG3ΔEnv) using FuGene transfection reagent
(Roche). Culture supernatants were harvested on day 3, stored at
−80 °C overnight, and then transferred to a liquid nitrogen freezer. The
p24 concentration in each stock was determined by using a commer-
cially available p24 ELISA kit (ABL Inc., Kensington, MD). Dr. Jeff Lifson
(AIDS Vaccine Program/NCI, Frederick, MD) provided the AT-2
inactivated HIV.
HIV-1 clade B positive plasma pool (abbreviated as USHIV+),
collected under an approved IRB protocol was generated as previously
described (Brown et al., 2005). Murine monoclonal IgG antibody (mAb
Hyb 278-01) speciﬁc to tetanus toxoid was purchased from Abcam Inc.
Humananti-HIV-1monoclonal antibodies 2F5 and 4E10 speciﬁc to gp41
and lipids and 2G12 speciﬁc to mannose residues on gp120 were
purchased from Polymun Scientiﬁc GmbH.
Virus capture assay for IgG monoclonal antibodies in the presence and
absence of soluble CD4 (sCD4)
The virus capture assay was modiﬁed from Nyambi et al. (1998).
Protein G coated 96-well microtiter plates (Thermo-Fisher) were
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monoclonal antibody (2F5, 4E10, 2G12) or control antibody (anti-
tetanus toxoidmAbHyb 278-01) in sodium carbonate buffer pH 9.6was
added to duplicate wells. The plates were sealed and incubated
overnight at 4 °C. The next day, plates were washed once with PBS
before the addition of 250 μl of blocking buffer (0.5% casein–0.5% BSA in
PBS) for 1 h at 37 °C. Plates were washed once with RMPI-1640 media.
Culture supernatant containing HIV-1 (100 ng of p24/ml)was diluted in
RPMI-1640 media and 100 μl was added to each well. The plates were
incubated for 1 h at 37 °C. Plates were washed 5 times with RPMI-1640
media before the addition of 200 μl of 1:5 dilution of lysis buffer in RPMI-
1640 media (p24 kit, ABL Inc.). Samples were stored at −80 °C until
assayed for p24 by ELISA according to the manufacturer's instructions.
The binding of the antibodies to the virus was determined by
the amount of viral p24 present in each case. Data are expressed as pg/
ml±SD.Eachexperimentwas repeatedaminimumof3 timesandall data
points were done in duplicate. In each experiment, virus only and mAb
only were also included. USHIV+ (1:100 dilution) and Hyb 278-01, an
irrelevant monoclonal antibody, served as the positive and negative
controls, respectively for the antibodies. The p24 values for the negative
control Hyb278-01 (anti-tetanus toxoid antibody) for all viral isolates
tested ranged from 0 to 7.7 pg/ml (background value). Therefore, a p24
value of ≥15.4 pg/ml, which was twice the background value was
considered positive.
Soluble CD4 (15 μg/well, Progenics Pharmaceuticals) was either
pre-incubated for 1 h at 37 °C with 100 μl of supernatant of different
HIV-1 clades (100 ng/ml of p24) and then added in duplicate to the
protein G coated plates containing mAbs 2F5 and 4E10 or sCD4 and
HIV-1 were simultaneously added to the plates. The remainder of the
procedure for the determination of p24 was carried out as described
above. The data obtained from the pre-incubation and the concurrent
addition of sCD4 and HIV-1 were indistinguishable, thus concurrent
addition was chosen as the standard method.
Analysis of 2F5 and 4E10 binding to AT-2 inactivated virus in the presence
or absence of sCD4 by surface plasmon resonance (SPR)
Measurement of AT-2 inactivated HIV-1 (Rossio et al., 1998;
Rutebemberwa et al., 2007) binding to 2F5was performedwith a Biacore
2000. AT-2 inactivated cladeD virus, A07412,was coupled to aﬂow cell of
a C1 sensor chip (Biacore) via primary amines according to the
manufacturer's speciﬁcations. HIV-1 A07412 was injected over the
activated surface at a concentration of 12.3 nM. Unbound free amine
groups were then quenched with ethanolamine. This immobilization
yielded approximately 2800 response units (RU) of virus. All experiments
were performed at 25 °C with 20 mM Tris–154 mM NaCl, pH 7.4.
Association of 2F5 (0–1000 nM) was measured for 60 s and dissociation
was measured for 180 s. Non-speciﬁc binding was subtracted. After each
injectionof 2F5, the chipwas regeneratedwith10 mMCHAPS followedby
50 mM HCl. The data are presented as a sensogram and data analyses
were performed using the BIAevaluation 4.1 software. In separate
experiments, mAbs 2F5, 4E10, USHIV+ sera, and normal human sera
were immobilized on a CM5 chip followed by blocking and capture of AT-
2 inactivated clade D virus, A07412. The data (RU) from a representative
experiment of two separate experiments is presented as a bar graph.
Additional experiments were conducted utilizing a Biacore T100. In
these experiments, proteinGwas immobilizedonaCM5chip (~4000RU).
ControlmAbHyb278-01speciﬁc to tetanus toxoid,mAb2F5, ormAb4E10
was then captured on the immobilized protein G chip. The non-speciﬁc
virus binding sites were then blockedwith 10% normal goat serum in PBS
(120 s, 50 μl/min). AT-2 inactivated clades D (A07412, 42.4 μg/ml) and A
(KNH, 71 μg/ml) viruseswere pre-incubatedwith sCD4 (0, 1, 5, 10 μg/ml)
at 37 °C for 1 hbefore injecting over theCM5chip containing2F5, 4E10, or
Hyb 278-01 (ﬂow rate of 50 μl/min with a 60 s association). After each
injection of virus/sCD4, the chip was regenerated with 50 mM NaOH for
45 sat aﬂowrateof50 μl/ml.Non-speciﬁcvirus/sCD4binding toHyb278-01 was subtracted from each reading. The data (RU) of the average of
three separate experiments is presented as a bar graph.
TZM-bl assay for TCID50 and neutralization (IC50)
The 50% tissue culture infectious dose (TCID50) was determined by
generating eight serial 4-fold dilutions of pseudovirus in triplicate in 96-
well culture plates in a total volume of 50 μl of growth medium
(DMEM). TZM-bl cells (1×104) were suspended in 50 μl of growth
medium containing 60 μg/ml DEAE-dextran and added to each of the
wells. After a 48 h incubation at 37 °C in a humidiﬁed 5% CO2–95% air
environment, the plates were analyzed using Brite-Light Luciferease kit
(Perkin-Elmer Life Sciences). 100 μl of the reconstituted substrate was
added to each well and the relative luminescence units (RLU) were
measured by aVictor 2 luminometer (Perkin-Elmer Life Sciences).Wells
producing RLU greater than 2.5 times background (signal of cells
without virus) were scored as positive (Li et al., 2005).
Pseudovirus neutralization assay
Virus (25 μl) was incubated with dilutions of test mAbs (25 μl) in
duplicate for 1 hat37 °C ina total volumeof 50 μl growthmedium in96-
well ﬂat-bottom culture plates (Corning-Costar). A 50 μl aliquot
containing 1×104 TZM-bl cells and 60 μg/ml DEAE-dextran was
added to each well. Each plate included wells with cells and virus
(virus control) or cells alone (background control). After 48 h, cellswere
lysed, luminescencewasmeasured as above and the 50% inhibitory dose
(ID50)wasdeﬁned as the dilution that resulted in a 50% reduction inRLU
compared to virus control wells after subtraction of background RLU
(Mascola et al., 2005). Titers were calculated as previously described
(Brown et al., 2008).
Quantitative measurements of envelope and Gag-p24 from pseudoviruses
293 T cell culture supernatants containing pseudoviruses for each of
the 5 clades were collected and the p24 concentration determined as
mentioned earlier. The clariﬁed cell culture supernatants containing the
pseudoviruses were concentrated by centrifugation at 150,000 rpm for
1 h. Proteins from each of the lysed virus preparationswere resolved by
SDS-PAGE on 4–20% gels (Invitrogen, Carlsbad, CA) under reducing
conditions and stained with ﬂuorescent dyes (Louder et al. 2005).
Known amounts of Escherichia coli expressed clade B-LAIIIIB-HXB2 p24
(provided byDr. Venigalla Rao, Catholic University of America) and CHO
expressed HIV-1IIIB gp140 (ABL Inc.) were run on the same gels along
with the test virus preparations to estimate the amount of p24 and
gp120 content of the viruses. Gelswere stainedﬁrstwith theﬂuorescent
dye Pro-Q® Emerald 300 and visualized on a Kodak GEL Logic 200
Imaging System followed by SYPRO® Ruby (Molecular Probes/Invitro-
gen) to detect and quantify glycoproteins and total protein, respectively.
The ﬂuorescence intensity of the bands for p24 and gp120 were
analyzed using ImageJ software (NIH) and the amount (ng) of p24 and
gp120were calculated from the standard curves. A representative gel of
three separate experiments is shown.
In separate experiments, proteins from each of the lysed virus
preparationswere resolved by SDS-PAGE on 4–20% gels under reducing
conditions and transferred onto PVDF membranes. The PVDF mem-
branes were probed with USHIV+ sera or normal human sera followed
by rabbit anti-human IgG-labeled with HRP (Thermo Scientiﬁc/Pierce,
Rockford, IL). The blots were developed with TMB membrane
peroxidase substrate system (KPL, Gaithersburg, MD).
Blue Native PAGE
The envelope proteins derived from the various pseudoviruses were
analyzed under native conditions using blue native gels followed by
Western blotting according to the manufacturer's instructions with
222 K.K. Peachman et al. / Virology 408 (2010) 213–223modiﬁcations from the procedure of Moore et al. (2006). Samples were
analyzed on 4–16% Bis-Tris NuPAGE gels (Invitrogen). The blots were
probed using an anti-gp120 cocktail or anti-gp41 cocktail, which
consisted of 1 μg/ml each of the mAbs 2 G12, b12, and 447-52D, or
20 μg/ml each of the mAbs 2F5 and 4E10, respectively. Rabbit anti-
human-HRP conjugate (1:2,500, Thermo Scientiﬁc/Pierce) was used as
the secondary antibody. The blotswere developedwith TMBmembrane
peroxidase substrate system (KPL).
Statistical analysis of experimental data
The data was analyzed for signiﬁcance using paired t-tests. A
p value≤0.05 was considered signiﬁcant and is depicted by an * in the
ﬁgures.
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